skip to Main Content

What is The International Liver CongressTM?

ILC, The International Liver CongressTM , is the annual EASL meeting, and the flagship event in EASL’s educational calendar.

ILC 2019

Every year in April, scientific and medical experts from a broad range of fields including hepatology, gastroenterology, internal medicine, cell biology, transplant surgery, infectious diseases, microbiology and virology, pharmacology, pathology but also radiology and imaging are coming to ILC from around the world to learn about the latest in liver research.

Most importantly, specialists share recent data, present studies and findings, and also discuss the hottest topics on liver disease. Due to all these, the annual ILC attracts around 10,000 delegates and 250 media representatives from all over the world. This makes ILC a truly international networking opportunity!

The International Liver CongressTM 2019 will take place 10-14 April 2019 at the Reed Messe Wien Exhibition & Congress Center, Vienna, Austria.

ILC 2019 venue address:

Reed Messe Wien Exhibition & Congress Center
Trabrennstraße 7,
1020 Vienna,

Station Krieau
Congress Entrance: Foyer D

Dicover the ILC 2018 Congress Report


ILC 2018, EASL’s 53rd annual meeting took place in Paris, France, and 9,669 delegates from 121 countries attended it. ILC’s importance is growing each year due to the fact that the field of hepatology is undergoing dramatic changes. Among them a major increase in metabolic liver diseases and liver cancer worldwide or highly effective drugs to cure hepatitis C are now available. But, most importantly, multiple novel treatment concepts are emerging for rare liver diseases and hepatitis B.

Therefore, during the opening ceremony, the ILC 2018 Honorary President, Tilman Sauerbruch, reminded the audience of the huge clinical and scientific advances that are made in hepatology, most of them during the course of his illustrious career. Most importantly, he highlighted that, for example, survival after the first liver transplantation performed by Thomas Starzl grew from just 0–23 days in 1963 to 1-year survival rates of 85% now, 55 years later. In other areas, in the same time period, all viral causes of hepatitis are identified. However, despite these real advances in  hepatology, many challenges remain…


Download the full ILC 2018 Congress Report

The ILC 2018 Congress Report is supported by grants from: Abbvie, Alexion Pharma GmbH, Boehringer Ingelheim, Gilead Sciences Europe Ltd, MSD and Pfizer.